Dr. Kathrin Ladetzki-Baehs began her career at MorphoSys, where she served in multiple roles within the R&D organization and ultimately as Director in Alliance Management, shepherding partnerships, and therapeutic projects in collaboration with international pharma partners. In 2018, she co-founded adivo GmbH, a MorphoSys spinout, alongside Dr. Markus Waldhuber, securing seed financing from High-Tech Gründerfonds, Occident and MorphoSys to develop CEASAR and FELIX, the first phage-display antibody libraries tailored for dogs and cats.